Clinical trial · Interventional
Open Label Immunotherapy Trial for Ovarian Cancer
Open Label, One-arm, 3-month Study of Once-daily Tablet of V3-OVA as Immunotherapy of Ovarian Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This Phase II will evaluate a new type of ovarian cancer immunotherapy based on a fundamentally new approach that has been successfully tested in a published clinical study of liver cancer. We will test new tableted preparation, V3-OVA, obtained from hydrolyzed, inactivated blood and tumors of patients with cancer of ovaries. Study will last 3 months, 20 patients will be recruited, given one pill per day for three months. The primary clinical endpoint is effect on tumor size and burden after 3 months. Secondary endpoint will be effect on levels of tumor markers on monthly basis compared to baseline.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tableted vaccine (V3-OVA) containing ovarian cancer antigens | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- V3-OVA treatment arm
- description
- Oral once daily pill of tableted vaccine (V3-OVA) containing ovarian cancer antigens administered for 3 months in 20 volunteers with ovarian cancer
- interventionNames
- Biological: Tableted vaccine (V3-OVA) containing ovarian cancer antigens
Primary outcomes (1)
- measure
- Changes in tumor size and burden compared to baseline
- timeFrame
- Monthly for 3 months
- description
- Intravaginal ultrasonography to measure changes in tumor size and burden
Secondary outcomes (1)
- measure
- Effect on level of serum tumor markers compared to baseline
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: Confirmed diagnosis of ovarian cancer Positive for CA125 tumor marker at above normal threshold level - Exclusion Criteria: Metastases to other sites \-
References
Publications (0)
Data not yet available